Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis

Sarcoidosis, Pulmonary Clinical Trial

— MetforminTOP  

Official title:

Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05910554
• Other study ID #: HP-00105681
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 1, 2024
• Est. completion date: March 1, 2025

Study information

• Verified date: March 2024
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double blinded, randomized, placebo controlled clinical trial of 40 participants with pulmonary sarcoidosis.

Primary Objective: To assess the steroid-sparing efficacy and safety of oral metformin therapy in participants with confirmed progressive pulmonary sarcoidosis for participants with steroid dependent disease.

Description:

The purpose of this study is to assess the efficacy of Metformin therapy in terms of steroid-sparing efficacy for sarcoidosis patients with steroid-dependent disease. Given that the morbidity and mortality has proven to be significant in patients with sarcoidosis, we believe there is unprecedented opportunity for improved clinical outcomes if the right interventional agent can be identified. In choosing steroid-sparing effect as the primary outcome, we will be able to detect changes in clinical outcomes that are important to patients and to the scientific community. We anticipate that these improvements will reduce or resolve the necessity of immunosuppressant therapy in these participants.

At least 40 participants will be randomized in equal proportion to metformin or placebo. Twenty completed participants per arm provide 80% power to reject (one-sided type I error of 5%) the null hypothesis that mean daily steroid use in the placebo treated group is less than in the metformin treated group using analysis of covariance adjusting for baseline average steroid use.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: March 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, as well as biopsy demonstrating granulomas, and no alternative for the cause of the granulomas, such as tuberculosis for at least one year prior to randomization. Tuberculosis must be ruled out by negative histology and culture.

2. Patients must be symptomatic of pulmonary sarcoidosis with FVC 45-85%

3. Steroid dosage of >10mg of prednisone for at least 6 months

Exclusion Criteria:

1. Inability to obtain consent

2. Age less than 18 years of age

3. Female participants of childbearing potential not willing use one of the following methods of birth control for the duration of the study and 90 days after study completion: condoms, sponge, foams, jellies, diaphragm, or non-hormonal intrauterine device, a vasectomized sole partner or abstinence. Females of childbearing potential must have a negative urine pregnancy test at screening visit

4. FVC predicted value is < 45%.

5. Creatine clearance of <30%.

6. History of idiopathic Lactate = 2.2 mmol/L or acidosis on study baseline metabolic profile

7. End-stage fibrotic pulmonary disease

8. Significant underlying liver disease

9. Allergy or intolerance to metformin

10. Allergy or intolerance to albuterol

11. Poor venous access for obtaining blood samples

12. Significant disorder, other than sarcoidosis, that would complicate the treatment evaluation, such as respiratory, cardiac, renal, neurologic, musculoskeletal or seizure disorders.

13. Use of an investigational drug within 30 days prior to screening or within 5 half-lives of the agent, whichever is longer.

14. Currently receiving >40mg prednisone.

15. ALT or AST =5 times upper limit of normal (ULN).

16. Leukopenia, as defined by WBC <3.0 cells/mm3 or absolute neutrophil count <1000 mm3

17. Breast feeding.

18. If patient is on immunomodulators, they must be on regimen for =3-month period and on a stable dose for = 4 weeks.

19. Most recent nuclear medicine scan or echocardiogram (if done), demonstrating cardiac ejection fraction <35%

20. Participant has persistent or active infections requiring hospitalization or treatment with antibiotics, antiretrovirals, or antifungals within 30 days of baseline. Minocycline and doxycycline are not considered antibiotics when used to treat sarcoidosis.

21. Any significant finding in the patient's medical history or physical or psychiatric exam prior to or after randomization that, in the opinion of the investigator, would affect patient safety or compliance or ability to deliver the study drug according to protocol.

22. On medications that, in the opinion of the investigator, would affect patient safety when taken with metformin

23. History of or receiving treatment for pulmonary hypertension. Receiving biologic medication within the 6 months prior to screening visit.

Related Conditions & MeSH terms

• Sarcoidosis
• Sarcoidosis, Pulmonary

Intervention

Drug:
• Metformin
Patients randomized to metformin will be assigned the active arm.
• Cellulose
Patients randomized to cellulose will be assigned the placebo arm.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Maryland, Baltimore

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the steroid-sparing efficacy and safety of oral metformin therapy in patients with progressive pulmonary sarcoidosis.	Mean daily oral corticosteroid dose post protocol-driven steroid taper at 24-weeks after randomization.	24 weeks
Secondary	To compare cumulative total steroid use between those randomized to metformin or placebo	• Average dose and cumulative total steroid use in the 24-week study horizon.	24 weeks